Clinical Trials Logo

Mixed Hyperlipidemia clinical trials

View clinical trials related to Mixed Hyperlipidemia.

Filter by:

NCT ID: NCT04885218 Completed - Clinical trials for Mixed Hyperlipidemia

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Start date: July 30, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SHR-1209 subcutaneous administration in patients with non-familial hypercholesterolemia and mixed hyperlipidemia after lipid-lowering therapy

NCT ID: NCT02008084 Completed - Clinical trials for Hypertriglyceridemia

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Start date: December 2013
Phase: Phase 2
Study type: Interventional

The purpose of this pilot study is to learn what study factors are important in designing a large, full-scale study of the effects of TRIA-662 on serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels. In this study, patients will first enter a Single-blind, dietary-controlled baseline period and receive 1000 mg placebo or active drug three times daily with meals (i.e., breakfast, lunch, and dinner) for 6 - 8 weeks. If the qualify to continue, they will then receive up to 2000 mg of active or placebo drug for an additional 14 weeks. Active drug will be given to 48 patients and placebo drug will be given to 16 patients. However, neither the patients not the clinic staff will know which patients are on active or placebo drug until the end of the study.

NCT ID: NCT01974297 Recruiting - Clinical trials for Mixed Hyperlipidemia

Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid

AVOCADO
Start date: July 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to compare combination atorvastatin/fenofibric acid 10/135mg with atorvastatin 20mg monotherapy in the mixed hyperlipidemia who were not at lipid goals with atorvastatin 10mg monotherapy.

NCT ID: NCT01956201 Recruiting - Clinical trials for Mixed Hyperlipidemia

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Start date: December 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Atorvastatin and Fenofibrate compared with atorvastatin monotherapy in mixed hypercholesterolemic patients.

NCT ID: NCT01012219 Completed - Clinical trials for Primary Hypercholesterolemia

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Start date: November 2009
Phase: Phase 1
Study type: Interventional

This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.

NCT ID: NCT00941603 Completed - Clinical trials for Primary Hypercholesterolemia

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Start date: June 29, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of SCH 900271 compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 8 weeks of treatment in participants with primary hypercholesterolemia (familial and nonfamilial) or mixed hyperlipidemia. The study will also evaluate the effect of SCH 900271 on non-high density lipoprotein cholesterol (non-HDL-C) and various other lipids and lipoproteins. The safety of SCH 900271 in this participant population will also be evaluated.

NCT ID: NCT00345657 Completed - Dyslipidemia Clinical Trials

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

Start date: July 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.

NCT ID: NCT00289900 Completed - Clinical trials for Mixed Hyperlipidemia

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

Start date: January 24, 2006
Phase: Phase 3
Study type: Interventional

This is a 12-week clinical trial in participants with mixed hyperlipidemia to study the effects of MK-0524B on lipids.The primary hypothesis is that MK-0524B (dosed as MK-0524A coadministered with simvastatin) will be superior to atorvastatin on decreasing the low denisity lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio for the following dose comparisons: 2g/20 mg MK-0524B versus 10 mg atorvastatin, 2g/40 mg MK-0524B versus 20 mg atorvastatin, 2g/40 mg MK-0524B versus 40 mg atorvastatin, and 2g/40 mg MK-0524B versus 80 mg atorvastatin.

NCT ID: NCT00269217 Completed - Clinical trials for Primary Hypercholesterolemia

Lipid Efficacy Study (0524B-022)(COMPLETED)

Start date: January 2006
Phase: Phase 3
Study type: Interventional

This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.

NCT ID: NCT00134238 Terminated - Clinical trials for Mixed Hyperlipidemia

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

RADIANCE 2
Start date: November 2003
Phase: Phase 3
Study type: Interventional

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia